Eli Lilly's Orforglipron: Obesity and Diabetes Pill Advances

Eli Lilly's orforglipron showed positive results in its second Phase 3 obesity trial, achieving a weight loss of 9.6% at the highest dose. With a consistent safety profile, global regulatory submissions are imminent, aiming for 2026 approval.